Category Archives: Epernicus Solutions

2009 Epernicus EPAC meeting

It was great seeing our customers and other thought leaders at our executive product advisory council meeting this week in Boston.  It was pretty incredible having so many people from top pharma and science organizations in one room talking about social media and really digging into the benefits and challenges.  Just finished going through the feedback forms — feedback has been very positive and and the most common suggestion was that we make the meeting longer next time.  Special thanks to GSK, Genzyme and the Broad Institute for your great case studies.  A few photos from the event:

posted by Cameron Snider, VP Business Development


Epernicus Launches Private Social Networking Solutions for Companies

We are excited to tell you about a new development at Epernicus – the creation of internal social networking platforms for pharma companies and non-profit research institutes. This new venture was inspired by companies who liked what they saw on our public site and realized they needed a community like Epernicus inside their institution.

Many companies and research institutes have thousands of researchers spread across multiple locations. As you might imagine, enabling effective communication and collaboration among researchers and between internal business units can be challenging. Social networking platforms can facilitate these interactions by enabling people to easily locate, learn about, and contact each other. They can also accelerate serendipitous interactions which, in turn, can speed up the path to discovery and development.

The private internal versions of Epernicus are highly tailored to fit the specific culture and needs of institutions ranging from non-profit research organizations to pharmaceutical companies to medical device companies. Our platforms can also be molded for companies outside the traditional biomedical research space.

You can learn more about Epernicus Solutions and see a brief slide show at Please contact us at with questions or comments.

posted by Vivek Murthy, Chairman